Information Provided By:
Fly News Breaks for September 22, 2017
JNJ
Sep 22, 2017 | 07:21 EDT
RBC Capital analyst Glenn Novarro raised his price target on Johnson & Johnson to $144 from $138, citing "positive feedback" from the company and better than expected prescription trends this quarter. He thinks that the company will report beat and raise Q3 results, driving the stock higher, and recommends buying the shares ahead of the results.